Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
about
Liposomes as nanomedical devicesSynthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic propertiesPeptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal modelsDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsNanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicNanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicinNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?Ovarian cancer treatment: The end of empiricism?Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerHigh cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies.Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances.Antibody-targeted nanoparticles for cancer therapy.Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin.Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignanciesDoes long-term treatment with Doxil® predispose patients to oral cancer?Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.Preparation of Folate-Conjugated Pluronic F127/Chitosan Core-Shell Nanoparticles Encapsulating Doxorubicin for Breast Cancer TreatmentTherapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies
P2860
Q28088315-5FDB0EA5-EFEA-4062-BCEB-024AA0EFFD4EQ28386509-03FCFE51-C3F6-407F-A867-5003D89755D9Q28538039-3D3A2F1E-CC00-4AA8-9076-1F620519CEA1Q30421664-F1BB9B11-3089-4B39-9CF1-1AF0DA69695AQ33681168-785E99D1-982E-4233-98F2-04DF84648A25Q33911056-3169BC2D-79D4-4131-A308-0C8CA723D97CQ34205189-E1C79106-2821-4C15-AA56-68148914719DQ34534023-CD613656-B765-490E-9E9E-1AEEDA82D08CQ36483166-B3B86019-C874-42D7-B8DB-1958F4F8E7D7Q36483169-9136F310-4E93-4EC7-A3FC-1FB24C31622FQ36554444-17D7FF41-0F5A-4FB1-89AC-68EBA65A72CAQ36714359-555C6034-270C-47CE-9C55-367D2D9935E9Q36728989-D0E4DF82-442C-4CD9-8D9C-BFF6CBC94CB0Q37576349-E80B8B11-4CFF-4AE2-97F9-D7E98F808861Q37721844-6C0DED7F-E36E-454A-87B0-01F2A7B93B60Q37805491-498B1C64-B3DF-489B-984A-13E88DD8E025Q37851969-8079E76E-0512-4F60-981E-2E9826CB9846Q39030223-C53A8C40-6893-4587-AC89-A3DA1F83E1DEQ42425711-29E23F8D-A6F5-4030-8352-ED9923B8D2CDQ42737898-075DA260-0248-4104-A421-ECFD7F8B382CQ48003875-C58AD0D2-ED32-45D5-8FE9-FA7B37D22A05Q48194008-5B5A0331-4D75-4AB5-822B-7A5076305540Q50003156-376C35A1-3802-49A1-A086-A5172F0201E5Q58910378-E64975C1-6EC9-4BB4-B8C4-61D4BA25AE14Q59113319-5772EEFA-9EAE-4F95-ACEE-BE8A2DC7BB9E
P2860
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pegylated liposomal doxorubici ...... ent epithelial ovarian cancer.
@en
type
label
Pegylated liposomal doxorubici ...... ent epithelial ovarian cancer.
@en
prefLabel
Pegylated liposomal doxorubici ...... ent epithelial ovarian cancer.
@en
P2093
P356
P1433
P1476
Pegylated liposomal doxorubici ...... ent epithelial ovarian cancer.
@en
P2093
A Hamilton
Allan Jacobs
D Mirchandani
E Andreopoulou
P304
P356
10.1093/ANNONC/MDL484
P577
2007-02-13T00:00:00Z